Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.

• Tác giả: Andrea Biondani, Ute Eisenberger, Guido Junge, Alexandre Karras, Moglie le Quintrec, Liz Lightstone, Junhao Liu, Matthias Meier, Carla M Nester, Manuel Praga, Giuseppe Remuzzi, Maria José Soler, Ronda Tawfik, Angelo J Trapani, Nicholas J A Webb, Edwin K S Wong
• Ngôn ngữ: eng
• Ký hiệu phân loại: 661.333 Potassium bicarbonate
• Thông tin xuất bản: United States : Kidney international reports , 2025
• Bộ sưu tập: NCBI
• ID: 673947

Tóm tắt

 INTRODUCTION: C3 glomerulopathy (C3G) is a complex, chronic, ultra rare, progressive primary glomerulonephritis, resulting from alternative complement pathway overactivation, leading to kidney failure in most patients, and frequent recurrence in transplants. Iptacopan (LNP023) is an oral, proximal complement inhibitor specifically targeting factor B, that selectively inhibits the alternative complement pathway. METHODS: This was a phase 2 extension study of 26 adult patients with native kidney (cohort A), or recurrent C3G (post kidney transplantation
  cohort B) receiving open label iptacopan. RESULTS: At 12 months, patients in cohort A had a significant reduction in 24-hour urine protein-to-creatinine ratio (UPCR
  57%
  CONCLUSION: These data provide a clinical rationale for further evaluation of long-term treatment of C3G with iptacopan.